In meta-regression , changes in plasma concentrations of adiponectin , leptin and CRP were associated with duration of treatment , but not with either change in BMI or baseline BMI values .
CONCLUSION Orlistat is effective in increasing plasma concentrations of adiponectin and decreasing those of leptin and CRP
AIMS To conduct a systematic review and meta- analysis of relevant r and omized clinical trials ( RCTs ) to ascertain the effect size of orlistat in modulating plasma levels of adipokines , ghrelin and C-reactive protein ( CRP ) .
Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study.
BACKGROUND Leptin , which has been identified as an antiobesity hormone , regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis . It appears that leptin may be an important factor in obesity management . Orlistat , a pancreatic lipase inhibitor , could reduce fat absorption and promote weight loss due to leptin metabolism . OBJECTIVE The purpose of this study was to investigate the effects of orlistat therapy on serum leptin levels . METHODS Obese women ( body mass index [ BMI ] , 30 kg/m(2 ) ) aged 18 to 50 years were r and omly assigned to receive 12 weeks of oral treatment with diet-orlistat ( 120 mg TID ) ( DO group ) or diet-placebo ( DP group ) . During the treatment period , patients were asked to eat a balanced diet of -1200 to 1600 kcal/d . Body composition was determined by bioelectrical impedance . Serum leptin levels were measured using radioimmunoassay at baseline and at study end . RESULTS A total of 24 patients entered the study ; 14 patients ( mean [ SE ] BMI , 37.7 [ 1.1 ] kg/m(2 ) ) received orlistat and 10 patients ( mean [ SE ] BMI , 39.4 [ 1.3 ] kg/m(2 ) ) received placebo . Compared with baseline , mean percentages of loss of body weight and fat mass after 12 weeks of treatment were significant in the DO group ( 9.1 % and 14.8 % , respectively ; both P = 0.001 ) and in the DP group ( 9.5 % and 17.6 % ; both P = 0.005 ) . The between-group differences were not statistically significant . Mean ( SE ) serum leptin levels also decreased significantly after treatment in the DO group ( 16.2 [ 1.2 ] vs 9.0 [ 1.0 ] ng/mL ; P = 0.001 ) and in the DP group ( 19.3 [ 2.1 ] vs 9.7 [ 1.4 ] ng/mL ; P = 0.005 ) . The between-group difference was not statistically significant . CONCLUSIONS In this study of obese women , orlistat treatment was associated with a similar decrease in body weight , fat mass , and serum leptin levels as placebo over a 12-week period . In this regard , short-term orlistat therapy may not provide an additional effect on serum leptin levels , and reduction in leptin levels were closely related to the decrease in fat mass
In meta-regression , changes in plasma concentrations of adiponectin , leptin and CRP were associated with duration of treatment , but not with either change in BMI or baseline BMI values .
CONCLUSION Orlistat is effective in increasing plasma concentrations of adiponectin and decreasing those of leptin and CRP
AIMS To conduct a systematic review and meta- analysis of relevant r and omized clinical trials ( RCTs ) to ascertain the effect size of orlistat in modulating plasma levels of adipokines , ghrelin and C-reactive protein ( CRP ) .